Autoimmune car t peers hit safety snags kyverna touts 1 year miv cel data

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 24 Sept, 12:07 UTC

As two Big Pharma players in the autoimmune CAR-T space face unexpected safety setbacks, Kyverna Therapeutics is reporting long-term clinical data that showcase sustained efficacy alongside an unblemished safety profile for its potential first-in-class candidate, miv-cel.

science

Sources

• T2Autoimmune car t peers hit safety snags kyverna touts 1 year miv cel dataFierce Biotech / Fierce Healthcare / MedCity / GEN24 Sept, 12:07